WO2007046083A3 - Compositions for treatment of eye diseases - Google Patents

Compositions for treatment of eye diseases Download PDF

Info

Publication number
WO2007046083A3
WO2007046083A3 PCT/IL2006/001168 IL2006001168W WO2007046083A3 WO 2007046083 A3 WO2007046083 A3 WO 2007046083A3 IL 2006001168 W IL2006001168 W IL 2006001168W WO 2007046083 A3 WO2007046083 A3 WO 2007046083A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
eye diseases
treatment
present
eye
Prior art date
Application number
PCT/IL2006/001168
Other languages
French (fr)
Other versions
WO2007046083A2 (en
Inventor
Yoav Sharoni
Joseph Levy
Yoram Sela
Zohar Nir
Original Assignee
Lycored Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycored Ltd. filed Critical Lycored Ltd.
Priority to MX2008004981A priority Critical patent/MX2008004981A/en
Priority to AU2006305546A priority patent/AU2006305546A1/en
Priority to JP2008535182A priority patent/JP2009515821A/en
Priority to EP06796159A priority patent/EP1937240A2/en
Publication of WO2007046083A2 publication Critical patent/WO2007046083A2/en
Priority to IL190779A priority patent/IL190779A0/en
Publication of WO2007046083A3 publication Critical patent/WO2007046083A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to pharmaceutical compositions comprising a mixture of carotenoids and adjuvants, which provides synergistic therapeutic potential. The compositions of the present invention, which can be administered orally or topically to the eye, are useful in preventing, attenuating or treating eye diseases such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and cataracts.
PCT/IL2006/001168 2005-10-16 2006-10-05 Compositions for treatment of eye diseases WO2007046083A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2008004981A MX2008004981A (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases.
AU2006305546A AU2006305546A1 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases
JP2008535182A JP2009515821A (en) 2005-10-16 2006-10-05 Composition for treating eye diseases
EP06796159A EP1937240A2 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases
IL190779A IL190779A0 (en) 2005-10-16 2008-04-10 Compositions for treatment of eye diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL171452 2005-10-16
IL17145205 2005-10-16

Publications (2)

Publication Number Publication Date
WO2007046083A2 WO2007046083A2 (en) 2007-04-26
WO2007046083A3 true WO2007046083A3 (en) 2011-05-19

Family

ID=37962894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/001168 WO2007046083A2 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases

Country Status (7)

Country Link
EP (1) EP1937240A2 (en)
JP (1) JP2009515821A (en)
AU (1) AU2006305546A1 (en)
IL (1) IL190779A0 (en)
MX (1) MX2008004981A (en)
RU (1) RU2008119234A (en)
WO (1) WO2007046083A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411431B2 (en) 2004-11-09 2014-02-12 カプロン インコーポレイテッド Methods and materials for skin care
US8022246B2 (en) * 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
DE202007012373U1 (en) * 2007-09-04 2009-01-08 Omnivision Gmbh Dietary supplements, sachets containing a dietary supplement and use of a dietary supplement
CA2741746C (en) * 2008-11-03 2016-08-23 Giuliani S.P.A. Therapeutic, dietary or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
CN105193777B (en) * 2009-01-19 2019-06-28 利科雷德有限公司 The synergistic combination of carotenoid and polyphenol
WO2011076869A1 (en) * 2009-12-22 2011-06-30 Aakerlund Hans-Erik Isolated green plant material
JP2011256118A (en) * 2010-06-07 2011-12-22 Kao Corp Il-8 and gm-csf expression inhibitor
JP2013540766A (en) * 2010-10-04 2013-11-07 カプロン インコーポレイテッド Cosmetic skin care composition
ES2754279T3 (en) * 2011-07-13 2020-04-16 Univ Georgia Use of xanthophyll carotenoids to improve visual performance and neuronal efficiency
CN103798808A (en) * 2012-11-15 2014-05-21 中国科学院大连化学物理研究所 Nutrient formula and application thereof to food or medicine for reliving asthenopia
EA035620B1 (en) 2014-08-11 2020-07-16 Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж Methods and composition for treating or preventing cataract
CN107106625A (en) * 2014-11-25 2017-08-29 利库德有限公司 The biological activity tomato compositions of lycopene with decrement
JP7105532B2 (en) * 2017-05-10 2022-07-25 ロート製薬株式会社 Composition for prevention, improvement or treatment of posterior segment disease
WO2019021299A1 (en) * 2017-07-25 2019-01-31 Tathagata Dutta A topical ocular suspension of antioxidants
WO2019087189A1 (en) * 2017-11-01 2019-05-09 Lycored Ltd. A method for improving ocular blood flow
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye

Also Published As

Publication number Publication date
AU2006305546A1 (en) 2007-04-26
MX2008004981A (en) 2008-10-17
WO2007046083A2 (en) 2007-04-26
JP2009515821A (en) 2009-04-16
RU2008119234A (en) 2009-11-27
EP1937240A2 (en) 2008-07-02
IL190779A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
WO2007046083A3 (en) Compositions for treatment of eye diseases
EP2514423A3 (en) Method of treatment of age-related macular degeneration (AMD)
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
MX2007008848A (en) Methods and compositions for the treatment of ocular disorders.
MX354184B (en) Alkoxy compounds for disease treatment.
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2009055006A8 (en) Deuterated darunavir
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
MX2019008963A (en) Composition containing ursodeoxycholic acid for prevention or treatment of visual impairment.
WO2007096886A3 (en) Composition and methods for treating and preventing age-related macular degeneration
WO2007089673A8 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
WO2004016214A3 (en) Methods and compositions for treatment of macular and retinal disease
WO2011137344A3 (en) Anti-s1p antibody treatment of patients with ocular disease
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190779

Country of ref document: IL

Ref document number: 2006305546

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006796159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008535182

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004981

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006305546

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008119234

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006796159

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0617420

Country of ref document: BR

Free format text: PEDIDO RETIRADO, UMA VEZ QUE, SEGUNDO O ART. 216 INCISO 2O DA LPI, O DOCUMENTO DE PROCURACAO NAO FOI PROTOCOLADO EM SESSENTA DIAS CONTADOS DA PRATICA DO PRIMEIRO ATO DA PARTE NO PROCESSO, E NAO HOUVE MANIFESTACAO DO REQUERENTE FRENTE A PUBLICACAO DO ARQUIVAMENTO DA PETICAO (11.6.1) NA RPI 2150 DE 20/03/2012.